80 related articles for article (PubMed ID: 1507728)
1. [Studies on the production of endogenous cytokines in patients with renal cell carcinoma].
Nakashima J; Tachibana M; Baba S; Deguchi N; Jitsukawa S; Hata M; Tazaki H
Nihon Hinyokika Gakkai Zasshi; 1992 Jul; 83(7):1110-7. PubMed ID: 1507728
[TBL] [Abstract][Full Text] [Related]
2. Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma.
Hillman GG; Puri RK; Kukuruga MA; Pontes JE; Haas GP
Clin Exp Immunol; 1994 Jun; 96(3):476-83. PubMed ID: 8004818
[TBL] [Abstract][Full Text] [Related]
3. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
4. [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].
Nomura K; Fujioka T
Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):822-30. PubMed ID: 8320887
[TBL] [Abstract][Full Text] [Related]
5. Activation of cytokine production and adhesion molecule expression on THP-1 myelomonocytic cells by macrophage colony-stimulating factor in combination with interferon-gamma.
Kimball ES; Kovacs E; Clark MC; Schneider CR
J Leukoc Biol; 1995 Nov; 58(5):585-94. PubMed ID: 7595061
[TBL] [Abstract][Full Text] [Related]
6. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
Kleinknecht S; Bichler KH; Strohmaier WL
Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
[TBL] [Abstract][Full Text] [Related]
7. Defective expression of interferon-gamma, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor alpha, and interleukin-6 in activated peripheral blood lymphocytes from glioma patients.
Urbani F; Maleci A; La Sala A; Lande R; Ausiello CM
J Interferon Cytokine Res; 1995 May; 15(5):421-9. PubMed ID: 7648444
[TBL] [Abstract][Full Text] [Related]
8. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
9. Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or HIV-infected subjects: role of interferon-gamma and tumor necrosis factor-alpha.
Gomez MJ; Torosantucci A; Quinti I; Testa U; Peschle C; Cassone A
Cell Immunol; 1993 Dec; 152(2):530-43. PubMed ID: 8258154
[TBL] [Abstract][Full Text] [Related]
10. Initial characterization of a lymphokine pathway for the immunologic induction of tumor necrosis factor-alpha release from human peripheral blood mononuclear cells.
Kornbluth RS; Gregory SA; Edgington TS
J Immunol; 1988 Sep; 141(6):2006-15. PubMed ID: 3139748
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy for renal cell carcinoma using IFN-gamma and OK-432: in vitro study.
Muraki J
Keio J Med; 1990 Mar; 39(1):21-5. PubMed ID: 2113148
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 and renal cell cancer: production, regulation, and growth effects.
Koo AS; Armstrong C; Bochner B; Shimabukuro T; Tso CL; deKernion JB; Belldegrum A
Cancer Immunol Immunother; 1992; 35(2):97-105. PubMed ID: 1596939
[TBL] [Abstract][Full Text] [Related]
13. [A new interferon-alpha assay system including indirect antitumor effect. Basic and clinical study of renal cell carcinoma].
Yoshihiro S
Nihon Hinyokika Gakkai Zasshi; 1992 Mar; 83(3):338-47. PubMed ID: 1564836
[TBL] [Abstract][Full Text] [Related]
14. TNF-alpha and IFN-gamma reverse IL-4 inhibition of lymphokine-activated killer cell function.
Swisher SG; Economou JS; Holmes EC; Golub SH
Cell Immunol; 1990 Jul; 128(2):450-61. PubMed ID: 2113430
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 and TNF alpha production in human renal cell carcinoma.
Gogusev J; Augusti M; Chrétien Y; Droz D
Kidney Int; 1993 Sep; 44(3):585-92. PubMed ID: 8231032
[TBL] [Abstract][Full Text] [Related]
16. [Expression of major histocompatibility complex antigens and intercellular adhesion molecule-1 (ICAM-1) on renal cell cancer. De novo expression and modulation by cytokines on renal cell cancer cell lines].
Tomita Y; Nishiyama T; Sato S; Fujiwara M
Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):232-8. PubMed ID: 1674973
[TBL] [Abstract][Full Text] [Related]
17. [Anti-neoplastic activity of a human recombinant tumor necrosis factor (Hu-rec-TNF) alone or in combination with human recombinant gamma-interferon, doxorubicin or cis-platinum on a human renal cell carcinoma line].
Gohji K; Hamami G; Kamidono S
Hinyokika Kiyo; 1987 Mar; 33(3):329-35. PubMed ID: 3113191
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
19. Effect of granulocyte-macrophage colony-stimulating factor treatment on phenotype, cytokine release and cytotoxicity of circulating blood monocytes and monocyte-derived macrophages.
Hennemann B; Kreutz M; Rehm A; Andreesen R
Br J Haematol; 1998 Sep; 102(5):1197-203. PubMed ID: 9753045
[TBL] [Abstract][Full Text] [Related]
20. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]